Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis

Oritavancin is a novel lipoglycopeptide with activity against Gram-positive organisms including streptococci, methicillin-resistant Staphylococcus aureus, vancomycin-resistant S aureus (VRSA), and vancomycin-resistant enterococci (VRE) [1–3]. The US Food and Drug Administration approved oritavancin...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Jennifer A., Feeney, Eoin R., Kubiak, David W., Corey, G. Ralph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677157/
https://www.ncbi.nlm.nih.gov/pubmed/26677455
http://dx.doi.org/10.1093/ofid/ofv156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677157/
https://www.ncbi.nlm.nih.gov/pubmed/26677455
http://dx.doi.org/10.1093/ofid/ofv156

Ejemplares similares